Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients-Reference-Cited by-同舟云学术

Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients

Published:2017-08 Issue:6 Volume:27 Page:526-534
ISSN:1044-5463
Container-title:Journal of Child and Adolescent Psychopharmacology
language:en
Short-container-title:Journal of Child and Adolescent Psychopharmacology

Author:

Findling Robert L.¹,Robb Adelaide S.²,DelBello Melissa³,Huss Michael⁴,McNamara Nora⁵,Sarkis Elias⁶,Scheffer Russell⁷,Poulsen Lis H.⁸,Chen Grace⁹,Lemming Ole Michael⁸,Areberg Johan⁸,Auby Philippe⁸

Affiliation:

1. Department of Psychiatry and Behavioral Sciences, Kennedy Krieger Institute and Johns Hopkins University, Baltimore, Maryland.

2. Department of Psychology and Behavioral Health, Children's National Health Systems, Washington, District of Columbia.

3. Department of Psychiatry and Behavioral Neuroscience, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

4. Universitätsmedizin, Klinik für Kinder- und Jugendpsychiatrie und -Psychotherapie, Mainz, Germany.

5. University Hospitals Case Medical Center, Cleveland, Ohio.

6. Sarkis Family Psychiatry, Gainesville, Florida.

7. Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine, Wichita, Kansas.

8. H. Lundbeck A/S, Valby, Denmark.

9. Clinical Pharmacology, Takeda Development Center Americas, Deerfield, Illinois.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Psychiatry and Mental health,Pediatrics, Perinatology, and Child Health

Link

http://www.liebertpub.com/doi/pdf/10.1089/cap.2016.0155

Reference21 articles.

1. Population Pharmacokinetic Meta‐Analysis of Vortioxetine in Healthy Individuals

2. Major Depression in the National Comorbidity Survey–Adolescent Supplement: Prevalence, Correlates, and Treatment

3. Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

4. Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial

5. Practice Parameter for the Assessment and Treatment of Children and Adolescents With Depressive Disorders

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies;European Child & Adolescent Psychiatry;2024-09-06

2. Vortioxetine’s impact on the autonomic nervous system in depressed children and adolescents: analysis of the heart rate variability;Scientific Reports;2024-06-23

3. VORTIOXETINE;Prescriber's Guide – Children and Adolescents;2024-05-02

4. Current Status of Pharmacokinetic Research in Children: A Systematic Review of Clinical Trial Records;Current Reviews in Clinical and Experimental Pharmacology;2022-12-23

5. Magnesium Potentiates the Vortioxetine’s Effects on Physical Performances and Biological Changes in Exercise-Induced Stress in Rats;Medicina;2022-09-28